We hypothesized that BCMA-targeted BTZ nanotherapy would target the tumor tissue, amplify the anti-tumor effect and enhance the immune therapeutic efficacy of the free drug in the MM tumor microenvironment, as well as overcome PgP-mediated drug resistance, with minimal toxicity to normal cells. The gene discussed is PGP; the disease is Miyoshi myopathy.